SCHEMBL3747965

SCHEMBL3747965

Cn1cnc(-c2ccc3ccccc3c2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.51
CYP2C19 P33261 2/20 0.51
CYP2E1 P05181 1/20 0.51
CYP2A6 P11509 1/20 0.51
CYP2B6 P20813 1/20 0.51
IRAK4 Q9NWZ3 1/20 0.49
CYP1A2 P05177 3/20 0.47
ALDH1A1 P00352 2/20 0.45
AR P10275 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MAPT P10636 2/20 0.45
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
KDM4E B2RXH2 1/20 0.45
NFKB1 P19838 1/20 0.45
GFER P55789 1/20 0.45
NFKB2 Q00653 1/20 0.45
RELA Q04206 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL311156 0.79 CYP2E1 (0.65) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL27784722 0.76 NPC1 (0.55) CYP2C9CYP2C19CYP1A2ALDH1A1AR
SCHEMBL1411712 0.75 TDP2 (0.43) CYP2C9CYP2C19CYP1A2ALDH1A1AR
SCHEMBL27910997 0.75 CHRNA7 (0.49) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL18806853 0.74 CYP2C9 (0.57) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL26914654 0.74 RAB9A (0.43) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL8250569 0.73 LRRK2 (0.59) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL11978725 0.73 CTRC (0.61) CYP2C9CYP2C19CYP2A6CYP1A2ALDH1A1
SCHEMBL4540057 0.73 CYP2E1 (0.49) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6
SCHEMBL12427182 0.73 NPC1 (0.49) CYP2C9CYP2C19CYP2E1CYP2A6CYP2B6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7838545-B2 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ALLERGAN, INC. (US) 2010-11-23 US disclosed
US-20090176828-A1 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2009-07-09 US disclosed
US-7396849-B2 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as α2 adrenergic agonists ALLERGAN, INC. (US) 2008-07-08 US disclosed
EP-1791833-A2 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS Allergan, Inc. (US) 2007-06-06 EP disclosed
WO-2006036497-A2 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ALLERGAN, INC. (US) 2006-04-06 WO disclosed
US-20060069144-A1 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ALLERGAN, INC. 2006-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069144-A1 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists ADRB2, ADRA2C, ADRA2A CYP2C9 1227/4885CYP2C19 1064/4885CYP2E1 587/4885
US-20090176828-A1 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS ADRB2, ADRA2C, ADRA2A CYP2C9 921/4885CYP2C19 732/4885CYP2E1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.